应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
03347 泰格医药
午间休市 04-11 12:05:00
26.350
+0.600
+2.33%
最高
26.450
最低
25.450
成交量
135.48万
今开
25.500
昨收
25.750
日振幅
3.88%
总市值
227.91亿
流通市值
32.41亿
总股本
8.65亿
成交额
3,536万
换手率
1.10%
流通股本
1.23亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
ST九芝(000989.SZ)子公司北京美科研发新药获得临床试验批准
智通财经 · 03-11
ST九芝(000989.SZ)子公司北京美科研发新药获得临床试验批准
ST九芝最新公告：控股子公司新药获临床试验批准
证券之星 · 03-11
ST九芝最新公告：控股子公司新药获临床试验批准
人福医药(600079.SH)：HW231019片获得药物临床试验批准通知书
智通财经网 · 03-11
人福医药(600079.SH)：HW231019片获得药物临床试验批准通知书
罗欣药业最新公告：注射用LX22001新增适应症获准开展临床试验
证券之星 · 03-11
罗欣药业最新公告：注射用LX22001新增适应症获准开展临床试验
莎普爱思最新公告：阿奇霉素滴眼液III期临床试验完成首例受试者入组
证券之星 · 03-11
莎普爱思最新公告：阿奇霉素滴眼液III期临床试验完成首例受试者入组
莎普爱思(603168.SH)：阿奇霉素滴眼液III期临床试验完成首例受试者入组
智通财经 · 03-11
莎普爱思(603168.SH)：阿奇霉素滴眼液III期临床试验完成首例受试者入组
罗欣药业(002793.SZ)：注射用LX22001新增适应症获准开展临床试验
智通财经 · 03-11
罗欣药业(002793.SZ)：注射用LX22001新增适应症获准开展临床试验
安徽柏拉阿图医药科技有限公司药品申请临床试验默示许可获受理
金融界 · 03-11
安徽柏拉阿图医药科技有限公司药品申请临床试验默示许可获受理
南京征祥医药有限公司药品申请临床试验默示许可获受理
金融界 · 03-11
南京征祥医药有限公司药品申请临床试验默示许可获受理
上海海思盛诺医药科技有限公司药品申请临床试验默示许可获受理
金融界 · 03-11
上海海思盛诺医药科技有限公司药品申请临床试验默示许可获受理
【广生堂：乙肝治疗创新药II期临床研究获得优化审评审批试点项目确认书】广生堂(300436.SZ)公告称，公司创新药控股子公司福建广生中霖生物科技有限公司收到北京市药品监督管理局下发的《优化创新药临床试验审评审批试点项目确认书》，同意GST-HG131联合GST-HG141的II期临床研究纳入试点项目，将有效缩短临床审评审批周期。GST-HG131是乙肝口服表面抗原抑制剂，目前全球范围内尚无同类产品上市；GST-HG141是新型乙肝核心蛋白或核衣壳调节剂，属于全新机制的在研抗乙肝病毒的一类新药。两者联合方案旨在探索基于核苷（酸）类似物NUC基础治疗上，在慢性乙型肝炎患者中的安全性、耐受性、有效性。该联合方案涉及的单药项目均已立项研发八年。
金融界 · 03-10
【广生堂：乙肝治疗创新药II期临床研究获得优化审评审批试点项目确认书】广生堂(300436.SZ)公告称，公司创新药控股子公司福建广生中霖生物科技有限公司收到北京市药品监督管理局下发的《优化创新药临床试验审评审批试点项目确认书》，同意GST-HG131联合GST-HG141的II期临床研究纳入试点项目，将有效缩短临床审评审批周期。GST-HG131是乙肝口服表面抗原抑制剂，目前全球范围内尚无同类产品上市；GST-HG141是新型乙肝核心蛋白或核衣壳调节剂，属于全新机制的在研抗乙肝病毒的一类新药。两者联合方案旨在探索基于核苷（酸）类似物NUC基础治疗上，在慢性乙型肝炎患者中的安全性、耐受性、有效性。该联合方案涉及的单药项目均已立项研发八年。
海王生物最新公告：全资子公司收到NEP018片药物临床试验批准通知书
证券之星 · 03-10
海王生物最新公告：全资子公司收到NEP018片药物临床试验批准通知书
甘李药业(603087.SH)：博凡格鲁肽(GZR18)注射液美国Ⅱ期临床试验完成首例受试者给药
智通财经 · 03-10
甘李药业(603087.SH)：博凡格鲁肽(GZR18)注射液美国Ⅱ期临床试验完成首例受试者给药
海王生物(000078.SZ)：NEP018片获得药物临床试验批准通知书
智通财经 · 03-10
海王生物(000078.SZ)：NEP018片获得药物临床试验批准通知书
【海王生物：NEP018片获药物临床试验批准】海王生物公告，全资子公司海王医药研究院的NEP018片近日获得国家药监局核准签发的《药物临床试验批准通知书》。通知书指出，经审查，NEP018片临床试验申请符合药品注册有关要求，同意其在晚期恶性实体瘤中开展临床试验。NEP018片是海王医药研究院自主研发的新型肿瘤靶向小分子激酶抑制剂，对设计靶点有良好选择抑制活性，针对胃肠道肿瘤具有良好的抑制作用。
金融界 · 03-10
【海王生物：NEP018片获药物临床试验批准】海王生物公告，全资子公司海王医药研究院的NEP018片近日获得国家药监局核准签发的《药物临床试验批准通知书》。通知书指出，经审查，NEP018片临床试验申请符合药品注册有关要求，同意其在晚期恶性实体瘤中开展临床试验。NEP018片是海王医药研究院自主研发的新型肿瘤靶向小分子激酶抑制剂，对设计靶点有良好选择抑制活性，针对胃肠道肿瘤具有良好的抑制作用。
泰格医药03月10日遭主力抛售315万元
市场透视 · 03-10
泰格医药03月10日遭主力抛售315万元
众生药业：RAY1225注射液III期临床试验获得组长单位伦理批件
证券之星 · 03-10
众生药业：RAY1225注射液III期临床试验获得组长单位伦理批件
众生药业：昂拉地韦片已完成与奥司他韦胶囊头对头III期临床试验并获积极结果
证券之星 · 03-10
众生药业：昂拉地韦片已完成与奥司他韦胶囊头对头III期临床试验并获积极结果
众生药业：RAY1225注射液治疗超重/肥胖III期临床试验获批，产品研发进入关键阶段
证券之星 · 03-10
众生药业：RAY1225注射液治疗超重/肥胖III期临床试验获批，产品研发进入关键阶段
加载更多
公司概况
公司名称：
泰格医药
所属市场：
SEHK
上市日期：
--
主营业务：
杭州泰格医药科技股份有限公司是一家从事为新药研发提供临床试验服务的中国控股公司。该公司经营两个分部。临床试验技术服务分部向生物制药和医疗器械公司提供临床试验运作服务和医学翻译等服务，帮助其进行创新药物、仿制药和医疗器械的临床试验。临床试验相关服务及实验室服务分部从事提供分析服务，比如数据管理和统计分析；后勤和执行支持服务，比如临床试验现场管理；行政协助，比如患者招募；以及咨询服务等。该分部同时通过其子公司为临床前和临床开发阶段提供实验室服务。该公司在国内市场和海外市场开展业务。
发行价格：
--
{"stockData":{"symbol":"03347","market":"HK","secType":"STK","nameCN":"泰格医药","latestPrice":26.35,"timestamp":1744344300007,"preClose":25.75,"halted":0,"volume":1354800,"delay":0,"floatShares":123000000,"shares":864948570,"eps":0.4974185215650987,"marketStatus":"午间休市","change":0.6,"latestTime":"04-11 12:05:00","open":25.5,"high":26.45,"low":25.45,"amount":35359500,"amplitude":0.038835,"askPrice":26.4,"askSize":5200,"bidPrice":26.3,"bidSize":20500,"shortable":3,"etf":0,"ttmEps":0.4974185215650987,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1744347600000},"marketStatusCode":3,"adr":0,"listingDate":1596729600000,"exchange":"SEHK","adjPreClose":25.75,"dividendRate":0.012082,"openAndCloseTimeList":[[1744335000000,1744344000000],[1744347600000,1744358400000]],"volumeRatio":0.695659,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"300347","market":"SZ","secType":"STK","nameCN":"泰格医药","latestPrice":44.81,"timestamp":1744345626000,"preClose":44.79,"halted":0,"volume":4929500,"delay":0,"premium":"-44.50"}},"requestUrl":"/m/hq/s/03347","defaultTab":"news","newsList":[{"id":"2518743285","title":"ST九芝(000989.SZ)子公司北京美科研发新药获得临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2518743285","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518743285?lang=zh_cn&edition=full","pubTime":"2025-03-11 20:22","pubTimestamp":1741695721,"startTime":"0","endTime":"0","summary":"智通财经APP讯，ST九芝(000989.SZ)公告，公司控股子公司九芝堂美科(北京)细胞技术有限公司(简称“北京美科”)研发的新药人骨髓间充质干细胞注射液近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意开展治疗孤独症的临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1260565.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK0188","BK1141","BK0185","03347","000989","BK0239","BK1576"],"gpt_icon":0},{"id":"2518374394","title":"ST九芝最新公告：控股子公司新药获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2518374394","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518374394?lang=zh_cn&edition=full","pubTime":"2025-03-11 20:09","pubTimestamp":1741694961,"startTime":"0","endTime":"0","summary":"ST九芝(000989.SZ)公告称，公司控股子公司九芝堂美科（北京）细胞技术有限公司研发的人骨髓间充质干细胞注射液近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意开展治疗孤独症的临床试验。该药物属于治疗用生物制品1类，目前主要通过康复训练、心理治疗和家庭干预等综合措施来改善患者的症状和提高生活质量。由于药物研发的特殊性，从临床试验到投产上市的周期长、环节多，易受到诸多不可预测的因素影响，临床试验进度及结果、未来产品市场竞争形势均存在诸多不确定性。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031100037626.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK0188","BK1141","BK0185","03347","000989","BK0239","BK1576"],"gpt_icon":0},{"id":"2518972587","title":"人福医药(600079.SH)：HW231019片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2518972587","media":"智通财经网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518972587?lang=zh_cn&edition=full","pubTime":"2025-03-11 16:37","pubTimestamp":1741682220,"startTime":"0","endTime":"0","summary":"人福医药(600079.SH)发布公告，公司控股子公司宜昌人福药业有限责任公司(以下简称“宜昌人福”，公司持有其80%的股权)近日收到国家药品监督管理局核准签发的HW231019片《药物临床试验批准通知书》，同意本品开展“用于急性疼痛的治疗”适应症的临床试验。HW231019为宜昌人福研发的新分子实体。HW231019片临床上拟用于急性疼痛的治疗。国内目前尚无同类型产品获批上市。截至目前，宜昌人福在该项目上的累计研发投入约为2,000万元人民币。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-03-11/doc-inephnhp2653486.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","BK0028","BK0070","BK0188","BK1141","600079","BK0012","03347","BK0185","BK0239","BK1576","BK0096"],"gpt_icon":0},{"id":"2518796873","title":"罗欣药业最新公告：注射用LX22001新增适应症获准开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2518796873","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518796873?lang=zh_cn&edition=full","pubTime":"2025-03-11 16:24","pubTimestamp":1741681454,"startTime":"0","endTime":"0","summary":"罗欣药业(002793.SZ)公告称，公司下属子公司山东罗欣药业集团股份有限公司、罗欣药业（上海）有限公司收到国家药品监督管理局下发的注射用LX22001新增适应症“预防重症患者应激性溃疡出血”《药物临床试验批准通知书》。注射用LX22001是钾离子竞争性酸阻滞剂类药物，此次新增适应症临床试验获得批准，有助于丰富产品管线，提升公司核心竞争力。但药物研发具有周期长、投入大的特点，且受行业政策等不确定因素影响，存在推进及研发效果不达预期的风险。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031100028169.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK0132","BK0001","BK1141","03347","002793","BK0201","08058","BK0239","BK1576"],"gpt_icon":0},{"id":"2518795785","title":"莎普爱思最新公告：阿奇霉素滴眼液III期临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2518795785","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518795785?lang=zh_cn&edition=full","pubTime":"2025-03-11 16:23","pubTimestamp":1741681410,"startTime":"0","endTime":"0","summary":"莎普爱思公告称，公司组织开展的阿奇霉素滴眼液III期临床试验已完成首例受试者入组。该试验采用多中心、随机、双盲、安慰剂对照设计，旨在评价阿奇霉素滴眼液在中国化脓性细菌性结膜炎患者中的有效性和安全性。截至公告披露日，该项目累计研发投入约1449.72万元人民币。根据相关法律法规要求，药物需完成临床试验后方可进行药品注册上市许可申请。公司将根据药物研发的实际进展情况及时履行披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031100028168.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK1141","03347","603168","BK0239","BK1576"],"gpt_icon":0},{"id":"2518606667","title":"莎普爱思(603168.SH)：阿奇霉素滴眼液III期临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2518606667","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518606667?lang=zh_cn&edition=full","pubTime":"2025-03-11 15:48","pubTimestamp":1741679293,"startTime":"0","endTime":"0","summary":"智通财经APP讯，莎普爱思(603168.SH)发布公告，近日，公司组织开展的阿奇霉素滴眼液III期临床试验完成首例受试者入组。阿奇霉素滴眼液III期临床试验，采用多中心、随机、双盲、安慰剂对照设计，评价阿奇霉素滴眼液在中国化脓性细菌性结膜炎患者中的有效性和安全性，已于2025年3月10日完成首例受试者入组。截至公告披露日，阿奇霉素滴眼液项目累计研发投入约1,449.72万元人民币。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1260297.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","III","BK1141","03347","BK4134","603168","BK0239","BK1576"],"gpt_icon":0},{"id":"2518128767","title":"罗欣药业(002793.SZ)：注射用LX22001新增适应症获准开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2518128767","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518128767?lang=zh_cn&edition=full","pubTime":"2025-03-11 15:45","pubTimestamp":1741679133,"startTime":"0","endTime":"0","summary":"智通财经APP讯，罗欣药业(002793.SZ)发布公告，近日，公司下属子公司山东罗欣药业集团股份有限公司、罗欣药业(上海)有限公司收到国家药品监督管理局下发的注射用LX22001新增适应症“预防重症患者应激性溃疡出血”《药物临床试验批准通知书》。公司在消化领域一直具备较强的市场竞争力，本次注射用LX22001新增适应症临床试验获得批准，体现了公司在保持该领域的技术优势的基础上持续发力，彰显了公司科技创新能力，有助于丰富产品管线，提升公司核心竞争力，符合公司战略发展需要。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1260294.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK0132","BK0001","BK1141","03347","002793","BK0201","08058","BK0239","BK1576"],"gpt_icon":0},{"id":"2518751295","title":"安徽柏拉阿图医药科技有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2518751295","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518751295?lang=zh_cn&edition=full","pubTime":"2025-03-11 12:18","pubTimestamp":1741666695,"startTime":"0","endTime":"0","summary":"3月11日，据CDE官网消息，安徽柏拉阿图医药科技有限公司联合申请药品“PA9159鼻喷雾剂”，获得临床试验默示许可，受理号CXHB2400308。安徽柏拉阿图医药科技有限公司，成立于2018年，位于宿州市，是一家以从事研究和试验发展为主的企业。主要股东信息显示，安徽柏拉阿图医药科技有限公司由浙江柏拉阿图医药科技有限公司持股60%、江山泰鼎企业管理有限公司持股20%、宿州市新区建设投资集团有限公司持股20%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/11121848651303.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["159938","BK1583","BK1574","BK1161","BK1141","03347","BK1576","09939","BK1515"],"gpt_icon":0},{"id":"2518751260","title":"南京征祥医药有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2518751260","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518751260?lang=zh_cn&edition=full","pubTime":"2025-03-11 12:18","pubTimestamp":1741666695,"startTime":"0","endTime":"0","summary":"3月11日，据CDE官网消息，南京征祥医药有限公司联合申请药品“ZX-7101A片”，获得临床试验默示许可，受理号CXHB2400307。公示信息显示，药品“ZX-7101A片”适应症：成人和12岁及以上青少年接触流感患者后的暴露后预防。南京征祥医药有限公司，成立于2020年，位于南京市，是一家以从事医药制造业为主的企业。通过天眼查大数据分析，南京征祥医药有限公司共对外投资了3家企业，知识产权方面有商标信息14条，专利信息17条，此外企业还拥有行政许可15个。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/11121848651302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["159938","BK1583","BK1574","BK1161","BK1141","03347","BK1576","09939","BK1515"],"gpt_icon":0},{"id":"2518751212","title":"上海海思盛诺医药科技有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2518751212","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518751212?lang=zh_cn&edition=full","pubTime":"2025-03-11 12:18","pubTimestamp":1741666695,"startTime":"0","endTime":"0","summary":"3月11日，据CDE官网消息，上海海思盛诺医药科技有限公司联合申请药品“HSK44459片”，获得临床试验默示许可，受理号CXHL2401453。公示信息显示，药品“HSK44459片”适应症：特应性皮炎。上海海思盛诺医药科技有限公司，成立于2022年，位于上海市，是一家以从事研究和试验发展为主的企业。企业注册资本100万人民币，实缴资本100万人民币。通过天眼查大数据分析，上海海思盛诺医药科技有限公司。主要股东信息显示，上海海思盛诺医药科技有限公司由海思科医药集团股份有限公司持股100%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/11121848651300.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["159938","BK1583","BK1574","BK1161","BK1141","03347","BK1576","09939","BK1515"],"gpt_icon":0},{"id":"2518622835","title":"【广生堂：乙肝治疗创新药II期临床研究获得优化审评审批试点项目确认书】广生堂(300436.SZ)公告称，公司创新药控股子公司福建广生中霖生物科技有限公司收到北京市药品监督管理局下发的《优化创新药临床试验审评审批试点项目确认书》，同意GST-HG131联合GST-HG141的II期临床研究纳入试点项目，将有效缩短临床审评审批周期。GST-HG131是乙肝口服表面抗原抑制剂，目前全球范围内尚无同类产品上市；GST-HG141是新型乙肝核心蛋白或核衣壳调节剂，属于全新机制的在研抗乙肝病毒的一类新药。两者联合方案旨在探索基于核苷（酸）类似物NUC基础治疗上，在慢性乙型肝炎患者中的安全性、耐受性、有效性。该联合方案涉及的单药项目均已立项研发八年。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518622835","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518622835?lang=zh_cn&edition=full","pubTime":"2025-03-10 19:58","pubTimestamp":1741607924,"startTime":"0","endTime":"0","summary":"广生堂(300436.SZ)公告称，公司创新药控股子公司福建广生中霖生物科技有限公司收到北京市药品监督管理局下发的《优化创新药临床试验审评审批试点项目确认书》，同意GST-HG131联合GST-HG141的II期临床研究纳入试点项目，将有效缩短临床审评审批周期。GST-HG131是乙肝口服表面抗原抑制剂，目前全球范围内尚无同类产品上市；GST-HG141是新型乙肝核心蛋白或核衣壳调节剂，属于全新机制的在研抗乙肝病毒的一类新药。两者联合方案旨在探索基于核苷（酸）类似物NUC基础治疗上，在慢性乙型肝炎患者中的安全性、耐受性、有效性。该联合方案涉及的单药项目均已立项研发八年。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/10195848633983.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1583","06978","BK1574","GST","BK1161","159992","BK1141","03347","300436","159837","BK0239","BK1576"],"gpt_icon":0},{"id":"2518784211","title":"海王生物最新公告：全资子公司收到NEP018片药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2518784211","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518784211?lang=zh_cn&edition=full","pubTime":"2025-03-10 17:00","pubTimestamp":1741597216,"startTime":"0","endTime":"0","summary":"海王生物(000078.SZ)公告称，公司全资子公司海王医药研究院近日收到国家药监局核准签发的《药物临床试验批准通知书》，同意NEP018片单药在晚期恶性实体瘤中开展临床试验。NEP018片是海王医药研究院自主研发的新型肿瘤靶向小分子激酶抑制剂，对胃肠道肿瘤具有良好的抑制作用。但新药研发过程周期长、环节多，存在技术、审核等多种不确定因素的影响，预计短期内对公司经营业绩不会产生重大影响。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031000022377.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK0028","BK0060","BK0188","000078","BK1141","BK0209","03347","BK0168","BK1576"],"gpt_icon":0},{"id":"2518166142","title":"甘李药业(603087.SH)：博凡格鲁肽(GZR18)注射液美国Ⅱ期临床试验完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2518166142","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518166142?lang=zh_cn&edition=full","pubTime":"2025-03-10 16:57","pubTimestamp":1741597060,"startTime":"0","endTime":"0","summary":"智通财经APP讯，甘李药业(603087.SH)公告，公司自主研发的博凡格鲁肽(研发代号：GZR18)注射液正在美国开展Ⅱ期临床试验，于近日成功完成首例受试者给药。据悉，博凡格鲁肽(研发代号：GZR18)注射液是一种每两周给药一次的GLP-1RA，旨在治疗成人2型糖尿病及肥胖/超重个体的体重管理。目前正在美国开展适应症为肥胖/超重的Ⅱ期临床试验，这也是全球首款与替尔泊肽头对头评估药物减重疗效的单靶点GLP-1RA。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259783.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","603087","BK1141","03347","BK0239","BK1576"],"gpt_icon":0},{"id":"2518218105","title":"海王生物(000078.SZ)：NEP018片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2518218105","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518218105?lang=zh_cn&edition=full","pubTime":"2025-03-10 16:28","pubTimestamp":1741595302,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海王生物 发布公告，公司全资子公司深圳海王医药科技研究院有限公司于近日收到国家药品监督管理局核准签发的NEP018片《药物临床试验批准通知书》，同意本品单药在晚期恶性实体瘤中开展临床试验。NEP018片是海王医药研究院自主研发、具有自主知识产权的新型肿瘤靶向小分子激酶抑制剂。经综合的临床前研究考察，NEP018片对设计靶点具有良好选择抑制活性，针对胃肠道肿瘤具有良好的抑制作用。该项目核心专利已获发明专利授权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK0028","BK0060","BK0188","000078","BK1141","BK0209","03347","BK0168","BK1576"],"gpt_icon":0},{"id":"2518218659","title":"【海王生物：NEP018片获药物临床试验批准】海王生物公告，全资子公司海王医药研究院的NEP018片近日获得国家药监局核准签发的《药物临床试验批准通知书》。通知书指出，经审查，NEP018片临床试验申请符合药品注册有关要求，同意其在晚期恶性实体瘤中开展临床试验。NEP018片是海王医药研究院自主研发的新型肿瘤靶向小分子激酶抑制剂，对设计靶点有良好选择抑制活性，针对胃肠道肿瘤具有良好的抑制作用。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518218659","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518218659?lang=zh_cn&edition=full","pubTime":"2025-03-10 16:27","pubTimestamp":1741595279,"startTime":"0","endTime":"0","summary":"海王生物公告，全资子公司海王医药研究院的NEP018片近日获得国家药监局核准签发的《药物临床试验批准通知书》。通知书指出，经审查，NEP018片临床试验申请符合药品注册有关要求，同意其在晚期恶性实体瘤中开展临床试验。NEP018片是海王医药研究院自主研发的新型肿瘤靶向小分子激酶抑制剂，对设计靶点有良好选择抑制活性，针对胃肠道肿瘤具有良好的抑制作用。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/10162748625635.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["159938","BK0028","BK1583","BK1574","BK0060","BK0188","BK1161","000078","BK1141","BK0209","03347","BK0168","BK1576","09939","BK1515"],"gpt_icon":0},{"id":"2518244601","title":"泰格医药03月10日遭主力抛售315万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518244601","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518244601?lang=zh_cn&edition=full","pubTime":"2025-03-10 16:17","pubTimestamp":1741594665,"startTime":"0","endTime":"0","summary":"03月10日, 泰格医药股价跌1.41%，报收35.00元，成交金额8821万元，换手率2.05%，振幅6.20%，量比0.80。泰格医药今日主力资金净流出315万元，连续3日净流出，上一交易日主力净流出981万元。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为72.22%，平均跌幅为1.72%。该股近5个交易日上涨5.11%，主力资金累计净流出1472万元；近20日主力资金累计净流入973万元，其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310171103abf29930&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310171103abf29930&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","03347","BK1576","BK1141"],"gpt_icon":0},{"id":"2518268658","title":"众生药业：RAY1225注射液III期临床试验获得组长单位伦理批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2518268658","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518268658?lang=zh_cn&edition=full","pubTime":"2025-03-10 11:37","pubTimestamp":1741577823,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业(002317)03月10日在投资者关系平台上答复投资者关心的问题。投资者提问：RAY1225注射液的III期临床试验预计何时完成？众生药业回复：您好！RAY1225注射液的临床试验目前进展顺利，并于近日获得RAY1225注射液治疗超重/肥胖参与者的III期临床试验组长单位伦理批件，众生睿创将在全国主要研究者的带领下，按照相关要求高质量、加速度、科学规范地推进III期临床试验。公司将及时依据信息披露规则履行信息披露责任。谢谢！以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031000010431.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK1141","BK0188","03347","BK1576","BK1583","BK0239","BK0077"],"gpt_icon":0},{"id":"2518621268","title":"众生药业：昂拉地韦片已完成与奥司他韦胶囊头对头III期临床试验并获积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2518621268","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518621268?lang=zh_cn&edition=full","pubTime":"2025-03-10 11:36","pubTimestamp":1741577817,"startTime":"0","endTime":"0","summary":"昂拉地韦片作为国内第一个获批临床的甲型流感病毒RNA聚合酶抑制剂，临床前研究结果表明，对包括奥司他韦耐药株、高致病性禽流感病毒株和巴洛沙韦耐药株等在内的多种不同亚型流感病毒株具有强大的抑制活性，已完成与奥司他韦胶囊头对头、安慰剂对照治疗成人甲型流感的III期临床试验结果表明：该试验获得了积极结果，本研究已达到方案预设的主要疗效终点指标，且安全性良好。目前昂拉地韦片正在审评审批阶段，并按照CDE要求正常推进中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031000010424.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","03347","002317","BK1583","BK1576","BK0239","BK1141"],"gpt_icon":0},{"id":"2518268646","title":"众生药业：RAY1225注射液治疗超重/肥胖III期临床试验获批，产品研发进入关键阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2518268646","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518268646?lang=zh_cn&edition=full","pubTime":"2025-03-10 11:36","pubTimestamp":1741577817,"startTime":"0","endTime":"0","summary":"投资者提问：一直很关注公司减肥药的进展，看到RAY1225注射液的III期临床试验获批了，这对公司未来业绩有何影响？RAY1225注射液治疗超重/肥胖参与者的III期临床试验组长单位伦理批件的获得，标志着该产品研发进入关键阶段，未来若顺利上市，对公司业绩具有积极作用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031000010426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","03347","BK1141","002317","BK0188","BK1583","BK0239","BK1576"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tigermed.net","stockEarnings":[{"period":"1week","weight":-0.1516},{"period":"1month","weight":-0.2916},{"period":"3month","weight":-0.0901},{"period":"6month","weight":-0.3563},{"period":"1year","weight":-0.2272},{"period":"ytd","weight":-0.164}],"compareEarnings":[{"period":"1week","weight":-0.0949},{"period":"1month","weight":-0.1304},{"period":"3month","weight":0.0848},{"period":"6month","weight":-0.0268},{"period":"1year","weight":0.2067},{"period":"ytd","weight":0.031}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"杭州泰格医药科技股份有限公司是一家从事为新药研发提供临床试验服务的中国控股公司。该公司经营两个分部。临床试验技术服务分部向生物制药和医疗器械公司提供临床试验运作服务和医学翻译等服务，帮助其进行创新药物、仿制药和医疗器械的临床试验。临床试验相关服务及实验室服务分部从事提供分析服务，比如数据管理和统计分析；后勤和执行支持服务，比如临床试验现场管理；行政协助，比如患者招募；以及咨询服务等。该分部同时通过其子公司为临床前和临床开发阶段提供实验室服务。该公司在国内市场和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.098232},{"month":2,"riseRate":0.6,"avgChangeRate":0.033576},{"month":3,"riseRate":0.6,"avgChangeRate":-0.015339},{"month":4,"riseRate":0.2,"avgChangeRate":-0.061583},{"month":5,"riseRate":0.25,"avgChangeRate":-0.024615},{"month":6,"riseRate":0.5,"avgChangeRate":-0.01435},{"month":7,"riseRate":0.5,"avgChangeRate":-0.014965},{"month":8,"riseRate":0,"avgChangeRate":-0.073433},{"month":9,"riseRate":0.4,"avgChangeRate":0.041739},{"month":10,"riseRate":0.4,"avgChangeRate":-0.034537},{"month":11,"riseRate":0.4,"avgChangeRate":0.029037},{"month":12,"riseRate":0.4,"avgChangeRate":0.033557}],"exchange":"SEHK","name":"泰格医药","nameEN":"TIGERMED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.32.3","shortVersion":"4.32.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰格医药(03347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰格医药,03347,泰格医药股票,泰格医药股票老虎,泰格医药股票老虎国际,泰格医药行情,泰格医药股票行情,泰格医药股价,泰格医药股市,泰格医药股票价格,泰格医药股票交易,泰格医药股票购买,泰格医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰格医药(03347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}